GSK, along with Pfizer Inc. – holding a 32% stake in Haleon – committed to refraining from selling any more shares in Haleon for a 60-day period following the settlement. Analysts, including Russ Mould from AJ Bell, suggest that GSK’s actions might influence Pfizer’s future decisions, considering its intention to sell down its shares.
Market Reactions
Shares in GSK, listed on the FTSE 100 index, experienced a marginal decline to 1,575.2 pence on Wednesday morning, down 0.4% from the previous close. Simultaneously, Haleon’s shares, also part of London’s blue-chip index, were valued at 327.15 pence, reflecting a 1.9% decrease.
Both GSK and Haleon declined to provide further comments on the transaction.
